Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders.
Bronchiectasis
Common variable immunodeficiency disorders
Forced expiratory volume in one second
Immunoglobulin M
St George Respiratory Questionnaire
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
13
04
2021
accepted:
09
12
2021
pubmed:
12
1
2022
medline:
21
4
2022
entrez:
11
1
2022
Statut:
ppublish
Résumé
Bronchiectasis is a frequent complication of common variable immunodeficiency disorders (CVID). In a cohort of patients with CVID, we sought to identify predictors of bronchiectasis. Secondly, we sought to describe the impact of bronchiectasis on lung function, infection risk, and quality of life. We conducted an observational cohort study of 110 patients with CVID and an available pulmonary computed tomography scan. The prevalence of bronchiectasis was 53%, with most of these patients (54%) having mild disease. Patients with bronchiectasis had lower median serum immunoglobulin (Ig) concentrations, especially long-term IgM (0 vs 0.25 g/l; p < 0.01) and pre-treatment IgG (1.3 vs 3.7 g/l; p < 0.01). CVID patients with bronchiectasis had worse forced expiratory volume in one second (2.10 vs 2.99 l; p < 0.01) and an annual decline in forced expiratory volume in one second of 25 ml/year (vs 8 ml/year in patients without bronchiectasis; p = 0.01). Patients with bronchiectasis also reported more annual respiratory tract infections (1.77 vs 1.25 infections/year, p = 0.04) and a poorer quality of life (26 vs 14 points in the St George's Respiratory Questionnaire; p = 0.02). Low serum immunoglobulin M concentration identifies patients at risk for bronchiectasis in CVID and may play a role in pathogenesis. Bronchiectasis is relevant because it is associated with frequent respiratory tract infections, poorer lung function, a greater rate of lung function decline, and a lower quality of life.
Identifiants
pubmed: 35015197
doi: 10.1007/s10875-022-01206-8
pii: 10.1007/s10875-022-01206-8
pmc: PMC9015976
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-581Informations de copyright
© 2022. The Author(s).
Références
J Allergy Clin Immunol. 2014 Jul;134(1):116-26
pubmed: 24582312
Respir Med. 2017 Jun;127:33-39
pubmed: 28502416
Eur Respir J. 2016 Jan;47(1):186-93
pubmed: 26541539
J Clin Immunol. 2007 May;27(3):308-16
pubmed: 17510807
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
pubmed: 1759018
Clin Exp Immunol. 2018 Feb;191(2):212-219
pubmed: 28990652
Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090
pubmed: 24043371
Respir Med. 2020 May;166:105940
pubmed: 32250872
Respir Res. 2019 Dec 4;20(1):275
pubmed: 31801528
J Clin Immunol. 2014 Feb;34(2):233-44
pubmed: 24338563
J Clin Immunol. 2017 May;37(4):329-331
pubmed: 28293897
Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):536-41
pubmed: 9279236
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
J Crit Care. 2018 Oct;47:30-35
pubmed: 29886064
Pediatr Pulmonol. 2020 Feb;55(2):292-299
pubmed: 31833673
J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):159-168.e3
pubmed: 28734862
J Clin Immunol. 2014 Jan;34(1):68-75
pubmed: 24136152
J Med Genet. 2016 Sep;53(9):575-90
pubmed: 27250108
Front Immunol. 2020 Mar 31;11:522
pubmed: 32296433
Ann Allergy Asthma Immunol. 2014 Oct;113(4):452-9
pubmed: 24880814
Stat Med. 2010 Dec 10;29(28):2920-31
pubmed: 20842622
J Clin Immunol. 2011 Jun;31(3):315-22
pubmed: 21365217
Front Immunol. 2020 Feb 07;11:149
pubmed: 32117289
Eur J Respir Dis Suppl. 1986;147:6-15
pubmed: 3533593
Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85
pubmed: 24328736
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):938-945
pubmed: 28351785
Clin Exp Immunol. 2016 Apr;184(1):73-82
pubmed: 26646609
J Clin Immunol. 2019 Jan;39(1):45-54
pubmed: 30547383
BMC Med. 2010 Dec 14;8:84
pubmed: 21156048